Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;36(1):54-9.
doi: 10.5581/1516-8484.20140014.

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia

Maria Helena de Almeida  1 , Laura Fogliatto  2 , Dulce Couto  3
Affiliations
Review

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia

Maria Helena de Almeida et al. Rev Bras Hematol Hemoter. 2014.

Abstract

Treatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires full adherence in order to maximize the likelihood of achieving optimal responses, and to minimize healthcare costs. In this article, we review some of the methods available for assessing compliance, the main consequences of nonadherence on treatment outcomes, major factors commonly associated with poor compliance, a few successful measures for improving adherence and the most accepted recommendations for proactively managing adverse events.

Keywords: BCR-ABL positive; Leukemia, chronic myeloid; Patient compliance; Therapeutics.

PubMed Disclaimer

References

    1. Cornelison M., Jabbour E.J., Welch M.A. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol. 2012;10(1):14–24. - PubMed
    1. Hughes T.P., Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematology Am Soc Hematol Educ Program. 2009:477–487. - PubMed
    1. Quintas-Cardama A., Cortes J.E., Kantarjian H. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma. 2008;(Suppl 3):S82–S88. - PubMed
    1. Bordonaro S., Raiti F., Di Mari A., Lopiano C., Romano F., Pumo V. Active home-based cancer treatment. J Multidiscip Healthc. 2012;5:137–143. - PMC - PubMed
    1. Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388. - PMC - PubMed

LinkOut - more resources